Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:EBSNASDAQ:GERNNASDAQ:LGNDNASDAQ:MNKD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEBSEmergent BioSolutions$6.19+11.8%$9.10$1.82▼$15.10$336.07M1.82.63 million shs1.52 million shsGERNGeron$1.77+10.6%$2.69$1.46▼$5.34$1.13B0.5315.25 million shs19.31 million shsLGNDLigand Pharmaceuticals$108.09+2.2%$114.42$67.72▼$129.90$2.08B1.12124,599 shs191,463 shsMNKDMannKind$5.21-0.8%$5.75$3.97▼$7.63$1.58B1.272.11 million shs2.17 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEBSEmergent BioSolutions+12.15%+6.73%-38.76%-28.99%+164.88%GERNGeron+10.63%+5.36%-37.23%-54.85%-5.85%LGNDLigand Pharmaceuticals+2.17%-6.34%-5.28%-4.77%+49.38%MNKDMannKind-0.76%+1.17%-6.80%-20.46%+17.08%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEBSEmergent BioSolutions4.2204 of 5 stars3.51.00.04.62.52.51.3GERNGeron4.407 of 5 stars4.43.00.01.32.93.30.6LGNDLigand Pharmaceuticals4.7067 of 5 stars3.54.00.04.42.82.51.9MNKDMannKind2.5392 of 5 stars3.60.00.00.03.40.81.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEBSEmergent BioSolutions 3.00Buy$14.33131.74% UpsideGERNGeron 2.83Moderate Buy$5.68221.01% UpsideLGNDLigand Pharmaceuticals 3.00Buy$147.0036.00% UpsideMNKDMannKind 3.13Buy$9.2176.86% UpsideCurrent Analyst Ratings BreakdownLatest EBS, LGND, GERN, and MNKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/12/2025GERNGeronHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/12/2025GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/4/2025EBSEmergent BioSolutionsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.002/27/2025GERNGeronBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$9.00 ➝ $4.002/27/2025GERNGeronScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$6.00 ➝ $4.002/27/2025GERNGeronStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.002/27/2025GERNGeronNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $5.002/27/2025GERNGeronB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$3.50 ➝ $2.002/27/2025MNKDMannKindWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.002/26/2025GERNGeronHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral2/18/2025GERNGeronB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.50 ➝ $3.50(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEBSEmergent BioSolutions$1.01B0.33$0.69 per share8.92$12.51 per share0.49GERNGeron$76.99M14.64N/AN/A$0.46 per share3.85LGNDLigand Pharmaceuticals$167.13M12.45$4.43 per share24.39$40.39 per share2.68MNKDMannKind$285.50M5.54N/AN/A($0.91) per share-5.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEBSEmergent BioSolutions-$760.50M-$3.73N/A2.99N/A-18.55%-9.91%-3.31%4/29/2025 (Estimated)GERNGeron-$184.13M-$0.27N/AN/AN/A-682.48%-67.53%-45.46%5/1/2025 (Estimated)LGNDLigand Pharmaceuticals$52.15M-$0.1643.0629.13N/A29.68%4.95%4.39%5/6/2025 (Estimated)MNKDMannKind-$11.94M$0.1074.4322.65N/A8.07%-17.74%8.68%5/14/2025 (Estimated)Latest EBS, LGND, GERN, and MNKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/3/2025Q4 2024EBSEmergent BioSolutions-$0.35$0.05+$0.40-$0.58$254.67 million$194.70 million2/26/2025Q4 2024GERNGeron-$0.04-$0.04N/A-$0.04$45.29 million$47.54 million2/26/2025Q4 2024MNKDMannKind$0.03$0.03N/A$0.03$74.99 million$76.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEBSEmergent BioSolutionsN/AN/AN/AN/AN/AGERNGeronN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEBSEmergent BioSolutions1.302.881.47GERNGeron0.042.892.74LGNDLigand PharmaceuticalsN/A12.4911.81MNKDMannKindN/A4.544.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEBSEmergent BioSolutions78.40%GERNGeron73.71%LGNDLigand Pharmaceuticals91.28%MNKDMannKind49.55%Insider OwnershipCompanyInsider OwnershipEBSEmergent BioSolutions1.20%GERNGeron3.00%LGNDLigand Pharmaceuticals5.90%MNKDMannKind3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEBSEmergent BioSolutions1,60054.34 million53.53 millionOptionableGERNGeron70636.90 million585.76 millionOptionableLGNDLigand Pharmaceuticals8019.26 million17.78 millionOptionableMNKDMannKind400303.59 million267.51 millionOptionableEBS, LGND, GERN, and MNKD HeadlinesRecent News About These CompaniesMannKind Corporation Showcases Positive Outcomes of Inhaled Insulin at ATTD 2025 with Anticipated sNDA Filing for Pediatric Use in 2025March 10 at 6:35 AM | quiverquant.comMannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22March 10 at 6:05 AM | globenewswire.comMannKind (NASDAQ:MNKD) Upgraded by StockNews.com to Buy RatingMarch 7, 2025 | marketbeat.comCarrera Capital Advisors Takes $1.02 Million Position in MannKind Co. (NASDAQ:MNKD)March 5, 2025 | marketbeat.comMannKind Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting NowMarch 1, 2025 | uk.finance.yahoo.comCantor Fitzgerald Raises Earnings Estimates for MannKindMarch 1, 2025 | marketbeat.comWedbush Reaffirms "Outperform" Rating for MannKind (NASDAQ:MNKD)February 28, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Raised to Buy at StockNews.comFebruary 28, 2025 | marketbeat.comMannKind (NASDAQ:MNKD) Announces Quarterly Earnings ResultsFebruary 27, 2025 | marketbeat.comMannKind Corporation (NASDAQ:MNKD) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | msn.comAnalysts Are Bullish on These Healthcare Stocks: Sarepta Therapeutics (SRPT), MannKind (MNKD)February 27, 2025 | markets.businessinsider.comMannKind (NASDAQ:MNKD) Stock Price Down 6.1% - Should You Sell?February 27, 2025 | marketbeat.comMannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In QuestionFebruary 27, 2025 | seekingalpha.comWells Fargo Sticks to Its Buy Rating for MannKind (MNKD)February 27, 2025 | markets.businessinsider.comMannKind Corp (MNKD) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...February 27, 2025 | gurufocus.comMannKind files automatic mixed securities shelfFebruary 27, 2025 | markets.businessinsider.comMannKind (MNKD) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | finance.yahoo.comMannKind Stock Surges After-Hours On Q4 Revenue Beat, Debt Reduction As Retail Investors Celebrate ‘Amazing Comeback’February 27, 2025 | msn.comQ4 2024 MannKind Corp Earnings Call TranscriptFebruary 27, 2025 | gurufocus.comMannKind Corporation (MNKD) Q4 2024 Earnings Call TranscriptFebruary 26, 2025 | seekingalpha.comMannKind: Q4 Earnings SnapshotFebruary 26, 2025 | chron.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEBS, LGND, GERN, and MNKD Company DescriptionsEmergent BioSolutions NYSE:EBS$6.18 +0.66 (+11.84%) Closing price 03/12/2025 03:59 PM EasternExtended Trading$6.24 +0.06 (+0.89%) As of 03/12/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.Geron NASDAQ:GERN$1.77 +0.17 (+10.63%) Closing price 03/12/2025 04:00 PM EasternExtended Trading$1.76 -0.01 (-0.51%) As of 03/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Ligand Pharmaceuticals NASDAQ:LGND$108.09 +2.30 (+2.17%) Closing price 03/12/2025 04:00 PM EasternExtended Trading$107.91 -0.18 (-0.17%) As of 03/12/2025 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.MannKind NASDAQ:MNKD$5.21 -0.04 (-0.76%) Closing price 03/12/2025 04:00 PM EasternExtended Trading$5.22 +0.00 (+0.10%) As of 03/12/2025 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ramaco Resources Pins Hopes on Coal's Untapped Potential Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy 3 Stocks Institutions Are Quietly Dumping Marvell’s 40% Drop Presents a Compelling Buying Opportunity These 3 Dividend Stocks Jumped 15% in a Month—More to Come? Why Wayfair Stock May Be a Hidden Gem for Value Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
